Remove 2025 Remove Chemotherapy Remove Immunization
article thumbnail

STAT+: Pharmalittle: We’re reading about drug shortages, Medicare spending on an Alzheimer’s drug, and more

STAT

billion in 2025 for the entire Medicare program, a spokesperson for the Centers for Medicare and Medicaid Services confirmed. These include oxytocin, which is used during childbirth; Rho(D) immune globulin, which helps some women during pregnancy; standard-of-care chemotherapy, pain and sedation medicines; and ADHD pills.

article thumbnail

The top 5 pharma M&A deals of 2020

pharmaphorum

Boston, US-based Alexion spent a lot of 2019 arguing the merits of remaining independent, saying that while Soliris is approaching the end of its patent life – with heavyweight competitors like Amgen already eyeing the biosimilar market for the drug – Ultomiris and its pipeline could help drives sales to $9 to $10 billion in 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BMS gets FDA nod for Opdivo as first adjuvant bladder cancer therapy

pharmaphorum

The PD-1 inhibitor has been approved to treat patients regardless of prior neoadjuvant chemotherapy, nodal involvement or PD-L1 status, and UC becomes the third indication for Opdivo as an adjuvant therapy after oesophageal/gastro-oesophageal cancer and melanoma.

FDA 78
article thumbnail

Five for Friday November 1: Celebrating Success in Advancing Medication Use Quality

PQA

Monitoring Oral Chemotherapy Outcomes A new study by specialty pharmacists from Vanderbilt Specialty Pharmacy detailed that a tailored clinical monitoring schedule focused on oral oncolytics with high rates of adverse events (AEs) slashed treatment interruptions by more than 50% and significantly reduced medication-related hospitalizations.

article thumbnail

Future of Bispecific Antibody: Exploring the Rise in Approvals

Roots Analysis

They are designed to recognize and bind to two specific molecules, such as a tumor cell and an immune cell, or two different parts of the same molecule. Bispecific antibodies are a type of antibody that can bind to two different targets at the same time. during the period 2023-2035.

article thumbnail

Lymphoma Action – championing the patient voice in cell therapy

pharmaphorum

1 Every year, 19,500 people are diagnosed with lymphoma 2 – a cancer affecting a certain type of white blood cell within the immune system – and can be classed as either slow or fast growing. Now, people living with particular types of lymphoma have individualised options beyond chemotherapy for the first time.”. Lymphoma Action.

article thumbnail

CHMP meeting highlights – January 2025

European Pharmaceutical Review

EMAs human medicines committee (CHMP) recommended eight medicines for EU marketing authorisation at its January 2025 meeting. Biosimilars given a positive opinion Dyrupeg (pegfilgrastim) to reduce the duration of neutropenia and help prevent febrile neutropenia following chemotherapy.